Evaxion A/S (NASDAQ:EVAX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Evaxion A/S (NASDAQ:EVAX) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $16.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. Maxim Group started coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Evaxion A/S Stock Performance

EVAX stock opened at $3.08 on Monday. The firm has a market cap of $25.69 million, a PE ratio of -2.33 and a beta of 0.28. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The stock has a 50-day moving average price of $3.87 and a 200-day moving average price of $4.63. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last announced its earnings results on Thursday, March 5th. The company reported $0.30 EPS for the quarter. As a group, equities research analysts expect that Evaxion A/S will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion A/S

Institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in Evaxion A/S in the 4th quarter valued at $38,000. Wesbanco Bank Inc. bought a new stake in shares of Evaxion A/S in the 4th quarter worth $48,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in shares of Evaxion A/S in the fourth quarter valued at about $72,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.